drugset / Trial / NCT00014755

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

NCT00014755

Phase 1 Completed 35 enrolled Fred Hutchinson Cancer Center
Treatment

Summary

OBJECTIVES: I. Determine the toxicity of total-body irradiation, anti-thymocyte globulin, and cyclophosphamide followed by syngeneic or autologous peripheral blood stem cell (PBSC) transplantation in patients with multiple sclerosis. II. Determine the disease response of patients treated with this regimen. III. Determine the safety and efficacy of filgrastim (G-CSF) for PBSC mobilization in this patient population.

Timeline

Start
1997-12
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic Intravenous
Subject Cyclophosphamide Other / unclassified Intravenous
Subject filgrastim Protein / enzyme biologic Subcutaneous
Background Prednisone Other / unclassified Oral

Indications